Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4,992,318
-
Total 13F shares
-
106,632,085
-
Share change
-
+5,323,299
-
Total reported value
-
$437,242,303
-
Put/Call ratio
-
11%
-
Price per share
-
$4.11
-
Number of holders
-
156
-
Value change
-
+$17,660,953
-
Number of buys
-
75
-
Number of sells
-
64
Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q1 2023
As of 31 Mar 2023,
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) was held by
156 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
106,632,085 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, Avoro Capital Advisors LLC, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, Bellevue Group AG, Rock Springs Capital Management LP, Sarissa Capital Management LP, and Avidity Partners Management LP.
This page lists
156
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.